Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

Summary

Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.

Timeline

Start

2010-09-01

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications